169 related articles for article (PubMed ID: 30605536)
1. Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.
Caldera F; Hayney MS; Cross RK
Inflamm Bowel Dis; 2019 May; 25(6):955-957. PubMed ID: 30605536
[No Abstract] [Full Text] [Related]
2. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
[TBL] [Abstract][Full Text] [Related]
3. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
Colombel JF
Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
[TBL] [Abstract][Full Text] [Related]
4. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
5. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Noell C; Arbeit R; Kanhoush R
Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study.
Bilgin E; Duran E; Ünaldı E; Kalyoncu U; Kiraz S; Ertenli İ
Rheumatology (Oxford); 2022 Aug; 61(9):e267-e269. PubMed ID: 35394013
[No Abstract] [Full Text] [Related]
7. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
[TBL] [Abstract][Full Text] [Related]
8. Elderly-Onset Varicella Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tofacitinib.
Abe N; Kudo T; Jodo S
Arthritis Rheumatol; 2018 Aug; 70(8):1233. PubMed ID: 29648682
[No Abstract] [Full Text] [Related]
9. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
[TBL] [Abstract][Full Text] [Related]
10. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
[TBL] [Abstract][Full Text] [Related]
12. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib: raising awareness of mycoses.
Dyer J; Morwood K; Choong K
Intern Med J; 2019 Jun; 49(6):805-806. PubMed ID: 31185527
[No Abstract] [Full Text] [Related]
15. [Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis].
Yamaoka K
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):181-9. PubMed ID: 27320933
[TBL] [Abstract][Full Text] [Related]
16. In brief: Risk of pulmonary thromboembolism and death with tofacitinib.
Med Lett Drugs Ther; 2019 Aug; 61(1579):136. PubMed ID: 31581159
[No Abstract] [Full Text] [Related]
17. Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy.
Brunet-Possenti F; Charpentier C; Bouhnik Y; Deschamps L; Descamps D; Moins-Teisserenc H; Descamps V
JAMA Dermatol; 2019 May; 155(5):629-631. PubMed ID: 30865238
[No Abstract] [Full Text] [Related]
18. Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
Seminario-Vidal L; Cantrell W; Elewski BE
J Drugs Dermatol; 2015 Aug; 14(8):901-2. PubMed ID: 26267737
[TBL] [Abstract][Full Text] [Related]
20. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
